# MariTide vs Weekly GLP-1s: Monthly Conjugate vs Weekly Agonists
> Note: PeptIQ is not a medical provider. Cross-trial comparisons are imperfect. Educational content only.
MariTide vs weekly GLP-1 searches are really asking: is monthly dosing the next adherence unlock — and does the efficacy still compete?
Side-by-Side Framing
| MariTide | Weekly dual/triple agonists | |
|---|---|---|
| Examples | Maridebart cafraglutide | Tirzepatide, retatrutide, CT-388, survodutide |
| Cadence | Every 4 weeks (± less frequent arms) | Every week |
| Molecule style | Peptide-antibody conjugate | Peptide multi-agonists |
| Phase 2 obesity signal | Up to ~20% @ 52 weeks (efficacy-style) | Program-dependent; many strong double-digit curves |
| Practical tracking | Monthly dose day + multi-day GI window | Weekly dose day + shorter spike pattern |
What Monthly Changes Psychologically
Weekly injectables create a ritual. Monthly injectables create a larger single exposure with a longer quiet middle. That can help busy people — and it can also make a bad titration week feel longer.
Track:
- Days 1–4 after monthly injection (symptom peak window)
- Mid-cycle hunger rebound (if any)
- Missed-month recovery rules from clinician/IFU
Efficacy Honesty
A ~20% MariTide Phase 2 mean does not automatically beat a ~20% weekly program mean from a different trial. Estimands, populations, lifestyle counseling, and discontinuation handling differ.
